SG11201909595VA - Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil - Google Patents
Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezilInfo
- Publication number
- SG11201909595VA SG11201909595VA SG11201909595VA SG11201909595VA SG 11201909595V A SG11201909595V A SG 11201909595VA SG 11201909595V A SG11201909595V A SG 11201909595VA SG 11201909595V A SG11201909595V A SG 11201909595VA
- Authority
- SG
- Singapore
- Prior art keywords
- donepezil
- therapeutic agent
- agent combining
- dementia therapeutic
- pyrazoloquinoline derivative
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003530 donepezil Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- UXYHZIYEDDINQH-UHFFFAOYSA-N C1=CNC2=C3C=NN=C3C=CC2=C1 Chemical class C1=CNC2=C3C=NN=C3C=CC2=C1 UXYHZIYEDDINQH-UHFFFAOYSA-N 0.000 title 1
- 206010012289 Dementia Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513692P | 2017-06-01 | 2017-06-01 | |
| PCT/JP2018/020638 WO2018221545A1 (ja) | 2017-06-01 | 2018-05-30 | ピラゾロキノリン誘導体とドネペジルの併用による認知症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909595VA true SG11201909595VA (en) | 2019-11-28 |
Family
ID=64455958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909595V SG11201909595VA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
| SG10202113198TA SG10202113198TA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202113198TA SG10202113198TA (en) | 2017-06-01 | 2018-05-30 | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11833146B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3632439B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7079777B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102627787B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110603040B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018276565A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019023569A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3060030A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2980131T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL270395B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019135834A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201909595VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018221545A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| CN116585316A (zh) | 2017-06-01 | 2023-08-15 | 卫材R&D管理有限公司 | 包含pde9抑制剂的药物组合物 |
| JP7177772B2 (ja) | 2017-06-01 | 2022-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| KR102271305B1 (ko) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272907B1 (ko) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272910B1 (ko) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR20220140960A (ko) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR20220146095A (ko) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
| KR102311224B1 (ko) * | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05132484A (ja) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| DE69518075T2 (de) | 1994-05-24 | 2001-03-22 | F. Hoffmann-La Roche Ag, Basel | Tricyclische dicarbonylderivate |
| GB9612710D0 (en) * | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
| WO1998030243A1 (en) * | 1997-01-08 | 1998-07-16 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| EP1537106A1 (en) | 2002-08-07 | 2005-06-08 | Mitsubishi Pharma Corporation | Dihydropyrazolopyridine compounds |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE102004004142A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| US20060035920A1 (en) | 2004-05-28 | 2006-02-16 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| WO2007032466A1 (ja) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | 複素環化合物、その製造方法並びに用途 |
| WO2008072779A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | キノキサリン誘導体 |
| AU2007332439A1 (en) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Therapeutic agent for urinary tract disease |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
| AU2010219598A1 (en) | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| ES2583528T3 (es) | 2010-09-07 | 2016-09-21 | Astellas Pharma Inc. | Compuesto de pirazoloquinolina |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| JP2013051639A (ja) | 2011-08-31 | 2013-03-14 | Kyocera Document Solutions Inc | 画像形成装置 |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| SI2573073T1 (sl) | 2011-09-26 | 2015-02-27 | Sanofi | Pirazolokinolinonski derivati, njihova priprava in njihova terapevtska uporaba |
| CN103930423B (zh) | 2011-10-07 | 2015-09-16 | 卫材Rd管理有限公司 | 吡唑并喹啉衍生物 |
| JP5666755B1 (ja) | 2013-04-05 | 2015-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体の塩およびその結晶 |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| CN116585316A (zh) | 2017-06-01 | 2023-08-15 | 卫材R&D管理有限公司 | 包含pde9抑制剂的药物组合物 |
| JP7177772B2 (ja) | 2017-06-01 | 2022-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| CN108563565B (zh) | 2018-04-08 | 2021-12-17 | 中国人民解放军海军工程大学 | 飞行着陆引导系统可靠性定量分析模型建立方法 |
-
2018
- 2018-05-30 BR BR112019023569-8A patent/BR112019023569A2/pt not_active IP Right Cessation
- 2018-05-30 CN CN201880030220.5A patent/CN110603040B/zh active Active
- 2018-05-30 JP JP2019521248A patent/JP7079777B2/ja active Active
- 2018-05-30 CA CA3060030A patent/CA3060030A1/en active Pending
- 2018-05-30 RU RU2019135834A patent/RU2019135834A/ru unknown
- 2018-05-30 IL IL270395A patent/IL270395B/en unknown
- 2018-05-30 SG SG11201909595V patent/SG11201909595VA/en unknown
- 2018-05-30 US US16/607,402 patent/US11833146B2/en active Active
- 2018-05-30 SG SG10202113198TA patent/SG10202113198TA/en unknown
- 2018-05-30 EP EP18810578.7A patent/EP3632439B1/en active Active
- 2018-05-30 WO PCT/JP2018/020638 patent/WO2018221545A1/ja not_active Ceased
- 2018-05-30 AU AU2018276565A patent/AU2018276565A1/en not_active Abandoned
- 2018-05-30 ES ES18810578T patent/ES2980131T3/es active Active
- 2018-05-30 KR KR1020197033197A patent/KR102627787B1/ko active Active
-
2022
- 2022-05-23 JP JP2022083947A patent/JP7288999B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL270395B (en) | 2022-08-01 |
| US11833146B2 (en) | 2023-12-05 |
| SG10202113198TA (en) | 2021-12-30 |
| JP7288999B2 (ja) | 2023-06-08 |
| JP7079777B2 (ja) | 2022-06-02 |
| US20200129501A1 (en) | 2020-04-30 |
| AU2018276565A1 (en) | 2019-11-07 |
| EP3632439A4 (en) | 2021-02-17 |
| CN110603040A (zh) | 2019-12-20 |
| RU2019135834A3 (cg-RX-API-DMAC7.html) | 2021-10-15 |
| EP3632439B1 (en) | 2024-03-27 |
| RU2019135834A (ru) | 2021-07-13 |
| IL270395A (cg-RX-API-DMAC7.html) | 2020-02-27 |
| KR102627787B1 (ko) | 2024-01-23 |
| CN110603040B (zh) | 2023-02-28 |
| WO2018221545A1 (ja) | 2018-12-06 |
| CA3060030A1 (en) | 2018-12-06 |
| EP3632439A1 (en) | 2020-04-08 |
| BR112019023569A2 (pt) | 2020-06-02 |
| ES2980131T3 (es) | 2024-09-30 |
| JPWO2018221545A1 (ja) | 2020-04-02 |
| KR20200010224A (ko) | 2020-01-30 |
| JP2022110143A (ja) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909590XA (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine | |
| IL270395B (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| PH12022550611A1 (en) | Brd9 bifunctional degraders and their methods of use | |
| NZ766835A (en) | Pharmaceutical compounds | |
| SA519401541B1 (ar) | [1، 5-a] مركبات بيرازولو كيناز ret بيريدين بها استبدال كمثبطات | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| SA519401544B1 (ar) | [1، 5-a] مركبات بيرازولو بيريدين بها استبدال كمثبطات كيناز معاد ترتيبه أثناء نقل العدوى | |
| MX2019013397A (es) | Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina. | |
| MX2018013529A (es) | Imidazo[1,2-b]piridazinas sustituidas, imidazo[1,5-b]piridazinas sustituidas, compuestos relacionados y su uso en el tratamiento de trastornos médicos. | |
| SG11201809859VA (en) | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | |
| MY155255A (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
| UY38766A (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
| MY145694A (en) | Spiroheterocyclic compounds and their uses as therapeutic agents | |
| SG11202103340PA (en) | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| MX394882B (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta) | |
| MX2020007062A (es) | Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. | |
| PL3432983T3 (pl) | Układ do leczenia jamy ciała pacjenta przy użyciu terapii fotodynamicznej i sposób przygotowania takiego układu | |
| MX379704B (es) | Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida | |
| NZ747797A (en) | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 |